Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Repro Med Systems, Inc. (OTC: REPR).

Full DD Report for REPR

You must become a subscriber to view this report.


Recent News from (OTC: REPR)

Rounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara Biotherapeutics
You need a different checklist and different mental models for different companies. I can never make it easy by saying, ‘Here are three things.’ You have to derive it yourself to ingrain it in your head for the rest of your life. - Charlie Munger Trading Analytics Welcome...
Source: SeekingAlpha
Date: May, 13 2018 03:46
RMS Medical Products Victory as U.S. Federal Circuit Court of Appeals Invalidates EMED Technologies Corp.'s Patent, Nullifying Infringement Claim
CHESTER, NY / ACCESSWIRE / April 9, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR; the "Company") is pleased to announce that the United States Court of Appeals for the Federal Circuit shot down EMED's appeal and that nine of the ten claims in EMED's patent were invali...
Source: ACCESSWIRE
Date: April, 09 2018 15:50
Daniel Goldberger Nominated for Election to RMS Board of Directors
CHESTER, NY / ACCESSWIRE / March 14, 2018 / The Board of Directors of Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that seasoned senior executive and business leader Daniel Goldberger has been nominated to stand for election to the board at the Company's Ann...
Source: ACCESSWIRE
Date: March, 14 2018 03:00
The Story Behind Growth: New Report Discusses Biocorrx and Repro-Med - Emerging Trends Within New Industry
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Biocorrx, Inc. (OTCQB: BICX) and Repro-Med Systems, Inc. (OTCQX: REPR), including recent technical analysis and consolidated fundamental information. ...
Source: ACCESSWIRE IA
Date: February, 26 2018 08:30
RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017
- Highest Reported Twelve Month Net Sales and Net Income in RMS History - Double-Digit Percentage Growth in Net Sales - Increased Profitability CHESTER, NY / ACCESSWIRE / February 13, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced the latest...
Source: ACCESSWIRE
Date: February, 13 2018 16:55
RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017
RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017
Source: OTC Markets
Date: February, 13 2018 00:00
RMS Medical Products Named to 2018 OTCQX Best 50
CHESTER, NY / ACCESSWIRE / January 26, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) is pleased to announce it has been named to the 2018 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year. The OTCQX Best 50 is an an...
Source: ACCESSWIRE
Date: January, 26 2018 11:00
OTC Markets Group Announces the 2018 OTCQX Best 50
NEW YORK , Jan. 24, 2018 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of the OTCQX®, OTCQB® and Pink® financial markets for 10,000 U.S. and global securities, today announced the 2018 OTCQX® Best 50, a ranking of top performing OTCQX companies ...
Source: PR Newswire
Date: January, 24 2018 07:00
CORRECTION: RMS Medical Products Announces New FDA Clearance, Warning Letter Closed, and Organizational Changes
- Resolution of FDA Warning Letter - Thanks to Eric Bauer for His Service as Chief Operating Officer - CEO Search Process Initiated - BOD Improvements CHESTER, NY / ACCESSWIRE / November 22, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), today a...
Source: ACCESSWIRE
Date: November, 22 2017 19:40
RMS Medical Products Announces New FDA Clearance, Warning Letter Cosed, and Organizational Changes
- Resolution of FDA Warning Letter - Thanks to Eric Bauer for His Service as Chief Operating Officer - CEO Search Process Initiated - BOD Improvements CHESTER, NY / ACCESSWIRE / November 22, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), today a...
Source: ACCESSWIRE
Date: November, 22 2017 16:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-151.301.251.301.2538,009
2018-08-141.311.311.311.31300
2018-08-131.321.311.381.2921,428
2018-08-101.321.3831.401.308,220
2018-08-091.321.421.421.319510,422

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-138,72821,42840.7318Short
2018-08-105,6488,22068.7105Short
2018-08-091,41210,42213.5483Cover
2018-08-0812,90021,58859.7554Short
2018-08-0716,10021,10076.3033Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on REPR.


About Repro Med Systems, Inc. (OTC: REPR)

Logo for Repro Med Systems, Inc. (OTC: REPR)

We design, manufacture and market proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications to be sold domestically and internationally.

 

 

 

Current Management

  • Andrew I. Sealfon / CEO
    • Mr. Andrew Sealfon cofounded Repro Med Systems, Inc. in and has been its President, Chief Executive Officer and head of research and development since that time, except from October through June , when Mr. Narishkin was Interim Chief Operating Officer. He is an electrical engineer and inventor and has been granted numerous U.S. patents. Mr. Sealfon is a graduate of Lafayette College.
  • Eric Bauer / COO
    • Mr. Bauer has more than years of executive management experience in a variety of manufacturing and FDA regulated industries. Prior to joining RMS Medical Products, Mr. Bauer was Chief Executive Officer of Value, LLC, a consulting and coaching business, from to . From to , Mr. Bauer served in the role of Chief Executive Officer for KAKO Beauty Products, a developer of prestige skin care goods, together with designing, packaging, marketing and implementation of a channel distribution strategy. From to , Mr. Bauer was Chief Executive Officer of Chemaid Laboratories, a Private Equityowned contract manufacturing company providing high quality skin care, haircare, fragrance and bath products to the prestige cosmetics industry. Mr. Bauer is a graduate of the State University of Buffalo with a BS in Industrial Engineering and has an MBA in Finance and Economics from the University of Rochester. Mr. Bauer also attended executive education classes at Columbia University, Massachusetts Institute of Technology and Duke University.
  • Karen Fisher / CFO, IR
    • Ms. Fisher has more than years of financial experience at a variety of industries, most recently serving as Assistant Controller, Senior Manager for Armored Autogroup, Inc., a worldwide consumer products company, from February to January . Before joining Armored Autogroup, Inc., she spent seven years at Gilman Ciocia, Inc., where she served in a variety of financial roles, including Chief Accounting Officer and Treasurer, and, earlier, as Controller. Before Gilman Ciocia, Inc., she held multiple financial management roles at The New York Times Company and Thomson Financial. Ms. Fisher is a Certified Public Accountant and a graduate of Arizona State University with a BS in accounting.
  • Fred Ma / CMO
    • Dr. Ma has over years of broad experience based on his neurosurgical practice, with significant emphasis in pharmaceuticals and medical device industries. Prior to joining RMS Medical Products, Dr. Ma was President and Managing Director of Medical Quality International, LLC, a pharmaceutical and medical device development consulting firm, from July to January . From June to July , Dr. Ma was the Chief Medical Officer and Board of Director at Innovacyn, Inc. a pharmaceutical company. Dr. Ma has a successful track record in all phases of product research and development culminating in final approvals, clearances, and commercialization. He is prominent within regulatory agencies and a multitude of professional organizations. Dr. Ma has directly designed and supervised numerous product developments, clinical trials, and has obtained many regulatory approvals and clearances in the United States and worldwide. Dr. Ma earned his M.D. degree from Capital University of Medical Sciences, Beijing, D.M.Sc. Doctorate of Medical Sciences equivalent to combined M.D. and Ph.D. degrees from University of Tokyo, Japan, and a Ph.D. from Rutgers University.
  • Andrew I. Sealfon / Chairman
    • Mr. Andrew Sealfon cofounded Repro Med Systems, Inc. in and has been its President, Chief Executive Officer and head of research and development since that time, except from October through June , when Mr. Narishkin was Interim Chief Operating Officer. He is an electrical engineer and inventor and has been granted numerous U.S. patents. Mr. Sealfon is a graduate of Lafayette College.
  • David W Anderson / Independent Director, Compensation Committee Member, Nominating Committee Member
    • Mr. Anderson was appointed to the Board of Directors in February, . Mr. Anderson has been in the medical device industry for over years and is currently the Chief Executive Officer for ORTEQ Ltd/CellCoTec Ltd. Previously, he held the role of Chief Executive Officer for Gentis, Inc. from through . He has also served on the board for ACell Inc., Regenerative Medicine for Woundcare and Aperion Biologics, ACL Replacement Technology , as well as served on several advisory committees. Mr. Anderson received a B.S. in Chemical Engineering from Cornell University and attended University of Minnesota for Graduate Studies in Microbiology.
  • Paul Mark Baker / Independent Director, Audit Committee Member
  • Joseph M Manko, Jr. / Independent Director, Compensation Committee Member, Nominating Committee Member
    • Mr. Manko was appointed to the Board of Directors on May , . Mr. Manko is the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP Horton Fund . The Horton Fund is a significant shareholder in the Company. Mr. Manko has over years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From Mr. Manko was a Partner and Chief Executive Officer of Switzerlandbased BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm s Special Situations and EventDriven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher amp Flom. Mr. Manko has served on the board of several companies in the biopharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries. Mr. Manko earned both his B.A. and Juris Doctorate from the University of Pennsylvania.
  • Mark Pastreich / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Mr. Pastreich is a businessman, and a longtime real estate investor and broker for the past years. He has served on numerous forprofit and notforprofit boards. Among his other various real estate holdings, he has been a partner in Casper Creek LLC for past years, which owns the building leased by the Company. Mr. Pastreich has a wealth of business acumen and experience.
  • Arthur J. Radin / Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Mr. Radin was appointed to the Board of Directors in January, . Mr. Radin, who started his career at Touche Ross amp Co., has been a partner in public accounting firms for years. He was a Partner with Radin, Glass amp Co., the Company s former independent auditors, from until January when he joined Janover LLC. As of January , he is a retired Partner and consultant at Janover LLC, a certified public accounting firm. He is a member of the New York State Society of Certified Public Accountants Editorial Board. Mr. Radin received a BA degree from Columbia College and a Master s in Business Administration from New York University.
  • Brad A. Sealfon / Compensation Committee Member, Nominating Committee Member
    • Mr. Brad Sealfon joined the Board of Directors in November, . Mr. Sealfon is the son of Mr. Andrew Sealfon, the Company s Chairman, President and Chief Executive Officer. From through December , Mr. Sealfon was employed at the Company in a variety of roles, most recently as the Marketing Director. Mr. Sealfon continues to consult with the Company on various projects. Mr. Sealfon is the founder of Stokequest, a traveling and consulting group for fellow adventurers and outdoor enthusiasts. Mr. Sealfon was also Head of Partnerships for the app WeShelter with a mission to end street homelessness. Mr. Sealfon also served on the Board of Directors for the Interactive Museum in Orange County, NY.

Current Share Structure

  • Market Cap: $50,968,541 - 03/09/2018
  • Authorized: 50,000,000 - 03/09/2018
  • Issue and Outstanding: 40,758,529 - 03/09/2018
  • Float: 21,159,887 - 05/05/2017

 


Recent Filings from (OTC: REPR)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 13 2018
Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 19 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: December, 21 2017

 

 


Daily Technical Chart for (OTC: REPR)

Daily Technical Chart for (OTC: REPR)


Stay tuned for daily updates and more on (OTC: REPR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: REPR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in REPR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of REPR and does not buy, sell, or trade any shares of REPR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/